Navigation Links
MWG and Operon Are Joining Forces
Date:12/3/2007

EBERSBERG, Germany and HUNTSVILLE, Ala., Dec. 3 /PRNewswire/ -- Operon Biotechnologies, Eurofins MWG and Eurofins Medigenomix - all part of the Eurofins Genomics network - announced today that they have agreed to work together in order to create a new worldwide leader in the competitive custom oligonucleotide market. With about $US 50M in revenue and state of the art high-throughput production facilities in all major markets (North America, Europe and Asia) the new network of companies intends to offer the market an unrivalled level of performance and efficiency in the custom DNA service area.

"Over the past 10 years overcapacity in the market has put a lot of pressure on all custom oligonucleotide synthesis service suppliers. Prices have decreased to a level where very few companies are able to keep up with the level of investment and innovation needed to meet the market demand for lower cost and higher quality of products and services. By joining the expertise, the resources and the experience of two major players in the field, we are convinced that we can take the next quantum leap which our customers expect from us," says Patrick Weiss, Managing Director of Operon Biotechnologies, Inc. and future CEO of Eurofins Genomics.

"Enabling Operon and Eurofins Genomics subsidiaries Eurofins MWG and Eurofins Medigenomix to work together strengthens our position in the custom oligonucleotides business and creates new opportunities for further development of additional services in the genomic services field. This will give the market, and in particular Eurofins customers in Biotechnology, Pharmaceutical, Food and Environment industries access to improved DNA services and innovative DNA-based testing," says Bruno Poddevin, Head of the Eurofins Genomics Services Cluster.

For further information please visit our websites http://www.mwgdna.com http://www.o
'/>"/>

SOURCE Operon Biotechnologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
2. Can cancer drugs combine forces?
3. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
4. The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus
5. Health Organizations Join Forces Around Quit-Smoking Help
6. The Cardiovascular Multimedia Network (CVMD) and the International Society of Endovascular Specialists (ISES) Join Forces to Educate Practitioners Worldwide Through Electronic Media
7. Medsphere & Keane Join Forces to Provide Healthcare Enterprises With Integrated Electronic Health Record & Revenue Cycle Management Systems
8. IAEA and NFCR join forces to fight cancer in developing world
9. VIB and UZ-KU Leuven join forces and bring state-of-the-art technology to Flanders
10. Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities
11. Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
(Date:5/22/2013)... genomic health disparities from the University of Miami Miller ... Medicine have teamed up to hold the second annual ... in Genomic Medicine." The theme of this year,s ... government to reduce these disparities. , Despite steady improvement ... within underserved groups continue to be more vulnerable to ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2
... The largest single-institution study of its kind has found ... after surgery to remove the prostate. Men in this ... following surgery indicated their cancer had recurred. ... in Florida and Minnesota suggest that patients and their ...
... procedure extends survival of cancer patients, , MONDAY, Sept. 28 ... a healthy breast removed after being diagnosed with breast cancer ... that this practice is actually beneficial in terms of improving ... in Cancer . , The researchers, led by ...
... UofT researchers have used nanomaterials to develop a ... severity of a patient,s cancer so that the disease ... Their groundbreaking work, reported Sept. 27 in Nature ... will become commonplace. "This remarkable innovation is an ...
... University School of Medicine (BUSM) are recommending that menopausal ... to having their annual mammogram screenings. These recommendations appear ... Journal of the North American Menopause Society . ... reduction in breast cancer mortality in women older than ...
... ... Research , ... September 28, 2009 -- Axiom Accelerated Patient Recruitment (Axiom), one of the ... messaging (SMS) services. , , , , ,"Mobile device outreach is the future of ...
... At ... Hell Doctors will join with their supporters in Washington D.C.,s Lafayette Park. , ... Washington, DC (PRWEB) September 28, 2009 --, ... single-payer advocacy tour, the Mad As Hell Doctors from Portland, Oregon will hold ...
Cached Medicine News:Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 2Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 3Health News:More Women Having Other Breast Removed 2Health News:More Women Having Other Breast Removed 3Health News:U of T researchers create microchip that can detect type and severity of cancer 2Health News:Researchers believe hormone therapy should not be stopped prior to mammograms 2Health News:Axiom Accelerated Patient Recruitment Rolls Out 2Health News:Mad As Hell Doctors to Hold Final "White Ribbon Rally" for Single Payer in Washington, D.C. on September 30th 2Health News:Mad As Hell Doctors to Hold Final "White Ribbon Rally" for Single Payer in Washington, D.C. on September 30th 3
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... 48-week investigational regimen yielded nearly double SVR rate ... protease inhibitor SCH 900518 presented at EASL annual ... SGP ) today reported that final ... its investigational oral hepatitis C protease inhibitor, in ...
... Potential of Fully Human Anti-PS Antibodies and ... Equivalent to the Human Antibody Inhibited Tumor ... More than 90%-DENVER and TUSTIN, Calif., April ... PPHM), a clinical stage biopharmaceutical company ...
Cached Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: